Does potentially inappropriate prescribing predict an increased risk of admission to hospital and mortality? A longitudinal study of the 'oldest old'.


Journal

BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548

Informations de publication

Date de publication:
28 Jan 2020
Historique:
received: 11 10 2019
accepted: 17 01 2020
entrez: 30 1 2020
pubmed: 30 1 2020
medline: 14 7 2020
Statut: epublish

Résumé

Potentially inappropriate prescribing (PIP) is associated with negative health outcomes, including hospitalisation and mortality. Life and Living in Advanced Age: a Cohort Study in New Zealand (LiLACS NZ) is a longitudinal study of Māori (the indigenous population of New Zealand) and non-Māori octogenarians. Health disparities between indigenous and non-indigenous populations are prevalent internationally and engagement of indigenous populations in health research is necessary to understand and address these disparities. Using LiLACS NZ data, this study reports the association of PIP with hospitalisations and mortality prospectively over 36-months follow-up. PIP, from pharmacist applied criteria, was reported as potentially inappropriate medicines (PIMs) and potential prescribing omissions (PPOs). The association between PIP and hospitalisations (all-cause, cardiovascular disease-specific and ambulatory-sensitive) and mortality was determined throughout a series of 12-month follow-ups using binary logistic (hospitalisations) and Cox (mortality) regression analysis, reported as odds ratios (ORs) and hazard ratios (HRs), respectively, and the corresponding confidence intervals (CIs). Full demographic data were obtained for 267 Māori and 404 non-Māori at baseline, 178 Māori and 332 non-Māori at 12-months, and 122 Māori and 281 non-Māori at 24-months. The prevalence of any PIP (i.e. ≥1 PIM and/or PPO) was 66, 75 and 72% for Māori at baseline, 12-months and 24-months, respectively. In non-Māori, the prevalence of any PIP was 62, 71 and 73% at baseline, 12-months and 24-months, respectively. At each time-point, there were more PPOs than PIMs; at baseline Māori were exposed to a significantly greater proportion of PPOs compared to non-Māori (p = 0.02). In Māori: PPOs were associated with a 1.5-fold increase in hospitalisations and mortality. In non-Māori, PIMs were associated with a double risk of mortality. PIP was associated with an increased risk of hospitalisation and mortality in this cohort. Omissions appear more important for Māori in predicting hospitalisations, and PIMs were more important in non-Māori in predicting mortality. These results suggest understanding prescribing outcomes across and between population groups is needed and emphasises prescribing quality assessment is useful.

Sections du résumé

BACKGROUND BACKGROUND
Potentially inappropriate prescribing (PIP) is associated with negative health outcomes, including hospitalisation and mortality. Life and Living in Advanced Age: a Cohort Study in New Zealand (LiLACS NZ) is a longitudinal study of Māori (the indigenous population of New Zealand) and non-Māori octogenarians. Health disparities between indigenous and non-indigenous populations are prevalent internationally and engagement of indigenous populations in health research is necessary to understand and address these disparities. Using LiLACS NZ data, this study reports the association of PIP with hospitalisations and mortality prospectively over 36-months follow-up.
METHODS METHODS
PIP, from pharmacist applied criteria, was reported as potentially inappropriate medicines (PIMs) and potential prescribing omissions (PPOs). The association between PIP and hospitalisations (all-cause, cardiovascular disease-specific and ambulatory-sensitive) and mortality was determined throughout a series of 12-month follow-ups using binary logistic (hospitalisations) and Cox (mortality) regression analysis, reported as odds ratios (ORs) and hazard ratios (HRs), respectively, and the corresponding confidence intervals (CIs).
RESULTS RESULTS
Full demographic data were obtained for 267 Māori and 404 non-Māori at baseline, 178 Māori and 332 non-Māori at 12-months, and 122 Māori and 281 non-Māori at 24-months. The prevalence of any PIP (i.e. ≥1 PIM and/or PPO) was 66, 75 and 72% for Māori at baseline, 12-months and 24-months, respectively. In non-Māori, the prevalence of any PIP was 62, 71 and 73% at baseline, 12-months and 24-months, respectively. At each time-point, there were more PPOs than PIMs; at baseline Māori were exposed to a significantly greater proportion of PPOs compared to non-Māori (p = 0.02). In Māori: PPOs were associated with a 1.5-fold increase in hospitalisations and mortality. In non-Māori, PIMs were associated with a double risk of mortality.
CONCLUSIONS CONCLUSIONS
PIP was associated with an increased risk of hospitalisation and mortality in this cohort. Omissions appear more important for Māori in predicting hospitalisations, and PIMs were more important in non-Māori in predicting mortality. These results suggest understanding prescribing outcomes across and between population groups is needed and emphasises prescribing quality assessment is useful.

Identifiants

pubmed: 31992215
doi: 10.1186/s12877-020-1432-4
pii: 10.1186/s12877-020-1432-4
pmc: PMC6986145
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

28

Subventions

Organisme : Department for Employment and Learning, Northern Ireland
ID : NA

Références

J Clin Pharm Ther. 2013 Oct;38(5):360-72
pubmed: 23550814
BMC Geriatr. 2019 Dec 19;19(1):357
pubmed: 31856733
Med Care. 1997 May;35(5):522-37
pubmed: 9140339
BMJ. 2019 Oct 16;367:l5674
pubmed: 31619406
Age Ageing. 2015 Mar;44(2):213-8
pubmed: 25324330
Aust N Z J Public Health. 2001 Jun;25(3):212-21
pubmed: 11494988
BMJ. 2008 Feb 2;336(7638):262-6
pubmed: 18198394
N Z Med J. 2007 Mar 02;120(1250):U2444
pubmed: 17339900
Lancet. 2002 Nov 23;360(9346):1623-30
pubmed: 12457784
BMC Med. 2015 Apr 07;13:74
pubmed: 25889849
Fam Med. 2005 May;37(5):360-3
pubmed: 15883903
Clin Endocrinol (Oxf). 2010 Dec;73(6):689-95
pubmed: 20184602
Acad Med. 2019 Apr;94(4):512-519
pubmed: 30277958
J Clin Epidemiol. 2013 Oct;66(10):1135-43
pubmed: 23860185
Heart Lung Circ. 2010 May-Jun;19(5-6):316-24
pubmed: 20444647
Drugs Aging. 2012 Jun 1;29(6):437-52
pubmed: 22642779
BMC Geriatr. 2012 Jun 29;12:33
pubmed: 22747503
Heart Lung Circ. 2012 Oct;21(10):639-43
pubmed: 22980672
BMJ Open. 2015 Sep 18;5(9):e008656
pubmed: 26384726
Aust N Z J Public Health. 2013 Apr;37(2):124-31
pubmed: 23551470
N Z Med J. 2002 Jan 25;115(1146):15-7
pubmed: 11936327
J Am Geriatr Soc. 2015 Nov;63(11):2227-46
pubmed: 26446832
PLoS One. 2013 Dec 31;8(12):e84039
pubmed: 24391876
Age Ageing. 2018 Mar 01;47(2):261-268
pubmed: 29281041
Ann Pharmacother. 2016 Jul;50(7):599-603
pubmed: 27083921
Ann Pharmacother. 2009 Jul;43(7):1239-44
pubmed: 19584381
Int J Epidemiol. 2015 Dec;44(6):1823-32
pubmed: 26082404
Int J Equity Health. 2007 Oct 03;6:12
pubmed: 17910778
Br J Clin Pharmacol. 2004 Jan;57(1):6-14
pubmed: 14678335
N Engl J Med. 2008 May 1;358(18):1887-98
pubmed: 18378519
N Z Med J. 2014 Jul 04;127(1397):13-29
pubmed: 24997698
Int J Clin Pharmacol Ther. 2008 Feb;46(2):72-83
pubmed: 18218287
Ther Adv Drug Saf. 2013 Aug;4(4):147-54
pubmed: 25114778
BMC Public Health. 2012 May 28;12:384
pubmed: 22640030

Auteurs

Karen Cardwell (K)

School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland. k.cardwell@qub.ac.uk.

Ngaire Kerse (N)

Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences University of Auckland, Auckland, New Zealand.

Carmel M Hughes (CM)

School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland.

Ruth Teh (R)

Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences University of Auckland, Auckland, New Zealand.

Simon A Moyes (SA)

Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences University of Auckland, Auckland, New Zealand.

Oliver Menzies (O)

Older People's Health, Auckland District Health Board, Auckland, New Zealand.

Anna Rolleston (A)

The Centre for Health, Tauranga, New Zealand.

Joanna B Broad (JB)

Department of Geriatric Medicine, Faculty of Medical and Health Sciences University of Auckland, Auckland, New Zealand.

Cristín Ryan (C)

School of Pharmacy & Pharmaceutical Science, Trinity College Dublin, The University of Dublin, College Green, Dublin, Dublin 2, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH